ABBV - AbbVie Inc.
Close
177.61
-0.570 -0.321%
Share volume: 50,467
Last Updated: Fri 27 Dec 2024 08:29:54 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$178.18
-0.57
-0.32%
Fundamental analysis
54%
Profitability
50%
Dept financing
50%
Liquidity
12%
Performance
71%
Performance
5 Days
0.45%
1 Month
-2.12%
3 Months
-8.00%
6 Months
6.04%
1 Year
15.70%
2 Year
9.95%
Key data
Stock price
$177.61
DAY RANGE
$177.65 - $179.66
52 WEEK RANGE
$155.21 - $207.32
52 WEEK CHANGE
$15.64
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
10/25/2024
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news